Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
Lova Sun, Elizabeth A. Handorf, Yunyun Zhou, Hossein Borghaei, Charu Aggarwal, Jessica R. Bauman
Topics & Concepts
MedicineSTK11KRASNivolumabOncologyInternal medicineImmunotherapyCancerColorectal cancerCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchLung Cancer Treatments and Mutations